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Abstract 
The majority of people receiving treatment for their heroin addiction, are prescribed methadone; for 
which there is an extensive evidence base. When treatment starts, people take their daily dose of 
methadone under supervision at a community pharmacy. Supervision guarantees methadone is 
taken as directed by the individual for whom it has been prescribed, helps to ensure individuals take 
their correct dose every day, and safeguards against diversion and overdose. However, individuals 
often fail to attend the pharmacy to take their methadone. Each missed dose is of concern. If a 
patient misses their daily dose of methadone, they will start to experience opiate withdrawal and 
cravings and are more likely to use heroin. If they miss three days dose, there are concerns that they 
may lose tolerance to the drug and may be at risk of overdose when the next dose is taken. Hence 
there is an urgent need to develop effective interventions for medication adherence. Research 
suggests that incentive-based medication adherence interventions may be very effective, but there 
are few controlled trials and the provision of incentives requires time and organisational systems 
which can be challenging in pharmacies. The investigators have developed the technology to deliver 
incentives by mobile telephone. This cluster randomised trial will test the feasibility of conducting a 
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future trial evaluating the clinical and cost effectiveness of using telephone delivered incentives 
(praise and modest financial rewards via text messaging) to encourage adherence with supervised 
consumption of methadone in community pharmacies. Three drug services (each with two or three 
community pharmacies supervising methadone consumption that will enrol 20 individuals, a total of 
60 participants) will be recruited and randomly allocated to deliver either i) telephone delivered 
incentives, ii) telephone delivered reminders or iii) no telephone system. Acceptability, recruitment, 
follow-up, and suitable measures of clinical and cost effectiveness will be assessed. Findings from 
this feasibility study will be assessed against stated progression criteria and used to inform a future 
confirmatory trial of the clinical and cost effectiveness of telephone delivered incentives to 
encourage medication adherence. 
Trial registration: ISRCTN58958179 (retrospectively registered).  
Keywords 
[opiate substitution treatment, methadone, supervised consumption, pharmacies, contingency 
management, medication adherence, financial incentives, behavioural reinforcement, heroin use] 
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1. Introduction 
Heroin addiction is a major public health issue. In 2011/12, there were an estimated 256,000 heroin 
(and other opiates) users in England [1]. Heroin and other opiates are responsible for more than 50% 
of all drug overdose deaths in England [2]. The costs to society of Class A drug use (including heroin 
use) were an estimated £15.4 billion in 2003/04[3]. In 2012, there were approximately 155,000 
people in treatment for heroin (or opiate) addiction in England. The majority are prescribed opiate 
substitution treatment (OST) with methadone or buprenorphine [4] for which there is an extensive 
evidence-base [5,6]. The National Institute for Health and Care Excellence (NICE) recommend 
substitute prescribing as the most effective treatment, alongside psychological therapies [7]. 
However, recovery from heroin addiction is a long-term process and many heroin users relapse into 
heroin use leading to high attrition rates in OST [8]. The Department of Health recommends 
methadone and buprenorphine consumption is supervised in the early stages of treatment [9,10]. 
Supervision guarantees methadone is taken as directed by the individual for whom it has been 
prescribed; and helps to ensure individuals take their correct dose every day to mitigate withdrawal 
or craving. Moreover, supervision safeguards against diversion onto the illicit market and overdose. 
Supervision may be relaxed after a few months if stability and clinical progress can be demonstrated. 
Pharmacists play an important role in dispensing OST medication, with a network of community 
pharmacists across England providing local availability of medication.  
Individuals often fail to attend the pharmacy to take their medication and those who do are very 
likely to miss multiple doses. In 2005, over a two-week period, 13% of prescriptions for OST had at 
least one missed pick-up (day when patient had not attended to take their dose) [11,12]. Of these, 
73% had one quarter of pickups missed and almost 19% had between one quarter and one half of 
pickups missed [11,12]. Also, 42% of OST patients at one London drug service had only partial or 
poor adherence to their medication in the previous 30 days, and more than one third of patients 
receiving supervised oral methadone had missed pick-ups [13]. For opiate patients it is important to 
take their medication every day, with each missed dose of concern. If a patient misses their dose it is 
likely that they will experience withdrawal symptoms and cravings which may lead them to use 
heroin. If they miss three doses/days, there are concerns that they may lose their tolerance to the 
drug and be at risk of overdose when the next dose is taken. Clearly the success of any 
pharmacotherapy depends heavily on medication adherence and as noted, patients in OST are not 
achieving full patient benefit (abstinence from illicit drugs) due to non-adherence of medication. 
Furthermore, non-adherence to medication is associated with non-attendance at medical and 
psychosocial appointments [14,15]. A pharmacist (under local agreement with the drug clinic 
prescriber) is normally unable to dispense the next day’s dose if a patient has failed to pick-up for 
three consecutive days [9,16,17]. Of concern is the pharmacists lack of consistent reporting to the 
prescribers about patient’s missed doses. Ten per cent of pharmacists stated that they would never 
or rarely report if a patient misses one or two doses to prescribers but would usually report if three 
doses were missed [11,12].  
Therefore, there is an urgent need to develop effective interventions for medication adherence [18]. 
A recent Cochrane review of psychological interventions for enhancing medication adherence 
(medication for substance misuse treatment was not included in this review) concluded that only 
some improved adherence and none were effective in encouraging long term medication adherence 
[19].  
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Contingency management (CM), based on the principles of operant conditioning, involves the 
systematic application of positive reinforcement to promote positive behaviour consistent with 
treatment goals and amplify patient benefit. CM in OST is effective at reducing illicit drug use 
[20,21], adherence to vaccination [22,23,24], HIV anti-retroviral and TB treatment [25,26,27,28]. 
NICE have recommended that CM be used in UK drug settings to target the reduction of drug use 
and encourage medication adherence [7, 29]. A recent systematic review of studies using incentives 
to reinforce medication adherence concluded that incentive-based interventions are promising but 
understudied (this review did not include OST studies) [30]. Effective methods to improve adherence 
need to be maintained for as long as the treatment is needed, requiring interventions that can be 
integrated into the care system in a cost-effective manner [19]. While CM requires time and 
organisational systems [31] which can be challenging in pharmacies dispensing to a high volume of 
patients, we believe CM delivered by technology might encourage medication adherence among 
individuals receiving OST while being resource light and cost-effective. While there is insufficient 
evidence to conclude that newer interventions such as text messaging reminders can improve 
adherence, there may be benefit to using text messaging in low-resource settings [19]. In a recent 
systematic review and meta-analysis of mobile telephone delivered CM interventions to promote 
behaviour change, CM delivered by mobile telephone was found to be effective at reducing tobacco 
and alcohol use. Only one study targeted medication adherence and this was to anti-retroviral 
medications among individuals with HIV and substance misuse [32].  
The authors have developed a telephone system for delivering CM via text messages [33].  The study 
described in this paper aims to assess the feasibility of conducting a future confirmatory randomised 
controlled trial (RCT) of the clinical and cost-effectiveness of a telephone system for delivering text 
message incentives to encourage adherence to supervised oral methadone. 
 
2. Material and methods 
2.1 Aim 
This study aims to assess the feasibility of conducting a future confirmatory RCT of the clinical and 
cost-effectiveness of i) telephone delivered incentives (positive reinforcement through text 
messages and financial incentives) to encourage adherence to supervised oral methadone among 
individuals receiving opiate treatment, compared with ii) text message reminders or iii) no text 
messages. The intention is that the future confirmatory trial would also use a cluster randomised 
design. Within each cluster, all participants will receive the same allocated condition. We believe it is 
necessary that all patients attending the same drug service (and pharmacy) for supervised 
consumption of methadone receive the same supervised methadone consumption scheme (i.e. 
telephone delivered incentives, reminders or neither) to ensure there is no risk of contamination by 
alternative treatments and eliminate possible patient self-selection by choosing pharmacies offering 
different schemes to receive their medication. 
The feasibility study has the following objectives: 1. Assess the willingness of clusters (drug services 
and allied community pharmacies) to be randomised; 2. Assess numbers of eligible patients relative 
to those screened, rates of recruitment and suitability of recruitment procedures; 3. Assess rates of 
follow-up at 12 weeks; 4. Test accuracy of recording/logging of attendance at the pharmacy;5. 
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Assess the acceptability of the study to patients; 6. Identify different options for quantifying the 
primary outcome (adherence to medication) for use in a future confirmatory trial and assess the 
utility and practicality of these options; 7. Characterise aspects of the primary outcome needed for a 
sample size calculation for a future confirmatory trial (e.g. For a continuous outcome, mean and 
standard deviation, an estimate of the intraclass correlation to inform a sensible range for the 
cluster trial design effect); and 8. Assess the most appropriate secondary outcome measures to 
determine patient benefit and cost-effectiveness, and 9. the availability and usefulness of existing 
data sets including existing pharmacy dispensing data sets. A process evaluation will be conducted 
alongside this feasibility trial to assess the acceptability of the intervention and the trial procedures 
and to determine how contextual factors and treatment process may impact on the primary 
outcome (attendance). Research ethics approval has been granted by London - South East Research 
Ethics Committee (18/LO/1722). 
2.2 Design and setting  
This feasibility study will use a 3-arm cluster randomised controlled design (Figure 1) where drug 
services and their allied community pharmacists are the cluster. It is intended that this design will 
give us the feasibility information we need to determine whether it is possible to conduct a future 
confirmatory trial.  
Three sites ( two National Health Service (NHS) substance misuse treatment services and one non-
NHS) will be recruited from 4 sites approached.  All sites will provide OST. This mix of non-NHS and 
NHS providers reflects current addiction service provision and will enhance the generalisability of 
the confirmatory study. At each site, two or three community pharmacies dispensing and supervising 
oral methadone to patients will be recruited. The criteria for enrolling community pharmacies will 
include: Pharmacists are willing and able to provide six days supervised consumption of oral 
methadone; Pharmacy has a consultation room on the premises or a separate designated area on 
the dispensing counter in which participants can consume their oral methadone under supervision; 
Pharmacy is currently providing supervised consumption of oral methadone to the patients at the 
drug clinic; Pharmacy is willing and able to provide dispensing records for participants over the 12-
week intervention period.  
We will enrol eligible and consenting participants at entry to OST at the participating service. They 
will be provided with OST including daily (6 days a week) supervised oral methadone at their 
pharmacy for 12 weeks and followed up at 12 weeks after enrolment. 
2.3 Characteristics of participants  
Participants will be those assessed for a new episode of OST at participating drug services (and will 
include either those newly presenting to the service or those already attending the service and being 
re- assessed for OST having not receiving OST for at least 4 weeks). Inclusion criteria for individual 
participants include: aged 18 years and over at enrolment; presenting to participating drug services 
for a new episode of OST (this excludes patients receiving a prescription for methadone or other 
opiate substitution medication within the last 4 weeks as well as those transferred from another 
service or prison); prescribed oral methadone; receiving supervised consumption of oral methadone 
from one of the participating pharmacies; receiving their supervised oral methadone six days a 
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week; owns a mobile phone; and willing and able to provide informed consent. Therefore, they must 
be able to read English and not require the service of an interpreter. 
Patients will be excluded if they cannot read English or would require the service of an interpreter to 
understand a brief oral description of the study; they have already entered the trial; or they have 
previously attended the service (drug clinic) and were discharged within the last three weeks. 
2.4 Recruitment 
Twenty participants will be recruited at each site (drug service) over a three-month recruitment 
period between mid-December 2018 and mid-March 2019 by drug service staff, giving a total of 60 
participants. Each individual presenting to the drug treatment clinic for a new episode of OST will be 
screened for eligibility. 
2.5 Processes/interventions and comparisons  
Interventions 
Opiate substitution treatment (OST). OST should be delivered in line with existing service protocols 
at sites. This would include psycho-social interventions usually delivered at the service. Each site will 
prescribe oral methadone for six days-a-week, with daily supervised consumption provided by a 
community pharmacy as part of usual treatment.   
Telephone system. The telephone scheme will be delivered for 12 weeks in line with current clinical 
guidelines which recommend that individuals receive their methadone supervised at a community 
pharmacy in the early stages of their treatment episode [10]. The telephone text message 
intervention will be discontinued if participants are no longer prescribed oral methadone or 
supervised consumption or they move to a non-participating drug service or pharmacy . 
The technology for telephone delivered incentives has already been developed by the authors, has 
been adapted and made operational for routine pharmacy use and has been piloted at two 
pharmacies. The technology uses internet-based software with an intelligent text message alert 
engine. It is hosted on and accessible through a secure website. The software will monitor all 
individuals and their supervised methadone appointments through an internet login on tablet 
computers at the pharmacy. The software is internet-based, thereby accessible from anywhere with 
an internet connection without the need to install and maintain separate standalone software. The 
internet-based software can contact individuals via mobile telephone text messages and keeps track 
of each time a patient logs in to attend a dosing appointment at the pharmacy, each time they do 
not log in to attend the appointment, and their monetary balance (if appropriate). The telephone 
system provides either: 
i. Telephone delivered incentives: Positive reinforcement through automated text messages of 
praise and modest financial incentives (CM), sent immediately after an individual logs in at 
their pharmacy (indicating they have taken their supervised methadone). Each time a 
participant attends their pharmacy and consumes their supervised oral methadone they will 
receive a text message giving positive reinforcement (praise) and earn a small financial 
reward of 50p. If they attend for six days consecutively, they will earn a bonus reward of £5. 
The total possible financial reward is therefore £8/week or £96 over 12 weeks. Participants 
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will be paid directly through pre-paid debit cards (an automated reward payment platform) 
issued by the study team. These allow for financial incentives to be electronically loaded 
onto the participant’s card once satisfaction of the target behaviour has been verified. If 
they do not attend, participants will receive a “shaping message” that evening informing 
them that they can still earn 50p if they attend the pharmacy (and take their dose) the 
following day. 
ii. Telephone delivered reminders: Text message reminders sent in the morning and afternoon 
to attend the pharmacy and take their supervised medication that day. Reminders will be 
sent each day for 12 weeks (comparator group).  
with a third group that will not receive any telephone text messages.  
Participants in all groups (including those not receiving telephone messages) will use a self-service 
internet login at their pharmacy to record their attendance and consumption of methadone. 
Participants will not have access to the tablet to login until they have received their supervised oral 
methadone. The telephone system also allows for the patients’ prescriber to receive weekly reports 
of their patient’s attendance and an early warning if their patient has missed two days. Prescribers 
for patients not receiving text messages will not receive these.  
The pharmacy will be unable to dispense the next day’s dose if a patient has failed to pick-up for 
three consecutive days. Therefore, the telephone system will be paused if a participant fails to 
attend their pharmacy and take their dose for three consecutive days.  The telephone system will be 
re-instated when the pharmacy is able to dispense methadone again to the participant (after they 
have had their dose reassessed by their prescriber). 
OST will continue to be delivered to participants after 12 weeks. 
2.6 Outcome measures 
2.6.1 Feasibility outcomes. 
(1) Enrolment rate of patients (Number enrolled per week, relative to those entering OST treatment, 
over the 12-week period);  
(2) Percentage of screened patients who are eligible for participation in the trial;  
(3) Percentage of eligible patients who consent to participation in the feasibility trial;  
(4) Percentage responding ‘yes’ to 12 × weekly text message sent by researchers asking if they 
received all text message incentives or reminders for previous week (this will indicate whether they 
have mobile telephone and whether they are receiving text messages); 
(5) Accuracy of attendance measurement measured by percentage of matches between (a) daily 
pharmacy dispensing record and (b) record of attendance and medication compliance recorded in 
self-service internet login at the pharmacy. A ‘match’ is defined as agreement between (a) and (b) as 
to whether a participant attended their supervised methadone replacement appointment on a given 
day; 
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(6) Number and percentage of participants followed-up for research interview at 12 weeks post 
enrolment, by arm, relative to those enrolled; 
The willingness of (7) drug services and (8) allied community pharmacies to participate - measured 
as the number and percentage of drug services and pharmacies enrolled relative to those 
approached; 
(9) Acceptability of the study to patients, drug service staff and pharmacists measured by qualitative 
views and experiences of patients, drug service staff and pharmacist. Focus groups will be held with 
between 5-8 participants at each service at a minimum of 10 weeks post enrolment. Interviews with 
drug service staff and pharmacists will be held at the end of the trial; 
2.6.2 Primary outcomes for exploration for a future confirmatory trial to look at the best ways to 
report missing doses/non adherence. Adherence to medication measured by (1) percentage of days 
during 12 weeks post-enrolment when medication was taken; (2) Median number of days during 12 
weeks post-enrolment when medication was not taken; (3) Likert scale categorising participants 
according to different levels of missed doses (number and percentage in each category), by arm; and 
(4) Number of days to missed dose analysed using repeated events survival analysis. Adherence to 
medication will be calculated by (i) enumerating all days during each participant’s intervention 
period, (ii) removing inactive days (those when the participants were paused, off script, or not 
supervised), and (iii) determining their attendance as indicated in the pharmacy records. Data from 
daily pharmacy dispensing data sets will be the authoritative source on adherence to medication. 
Aspects of the primary outcome measures needed for a sample size calculation for a future 
confirmatory trial including (5) appropriate summary statistics (for example, mean and standard 
deviations for continuous outcomes); (6) estimate of the intraclass correlation (ICC) for the clusters.   
Information from three sites will provide an initial estimate of ICC, which will inform our sample size 
calculations for a larger trial. However, this estimate will be supplemented by information from 
previous studies with populations from primary care [34,35] and opiate substitution treatment [ 20, 
21, 36] which suggest values of ICC less than 0.05; and (7) qualitative information on the availability 
and usefulness of existing pharmacy dispensing data sets. 
2.6.3 Secondary outcomes of a future confirmatory trial. (8) Number and percentage retained in 
treatment over the 12-week intervention period. Illicit drug use measured by Opiate Treatment 
Index (Section 2 – Drug Use) (Validated)[37] including: (9) Number and percentage using illicit street 
drugs in past 30 days; (10) Median number of days used illicit street drugs in past 30 days; (11) 
Median number of days injected illicit street drugs use in past month; (12) Route of use 
(number/percentage for each); (13) Average cost of each drug used on average day. (14) Alcohol Use 
Disorders Identification Test (AUDIT) (Validated, mean total score)[38]; (15) Hospital Anxiety and 
Depression Scale (HADS) (Validated, mean total anxiety and depression subscale scores)[39]; (16) 
Social functioning measured using the Opiate Treatment Index (Validated, mean social functioning 
subscale score)[37]; (17) Physical and mental health status (Short form-36 subscale mean 
scores)[40]; and (18) Missing data by questionnaire and time point. 
2.6.4 Sociodemographic characteristics. Age (mean and standard deviation); gender (number and 
percentage in each group); ethnicity (number and percentage in each group); employment status 
(number and percentage in each group); living situation (number and percentage in each group). 
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2.6.5 Outcomes for economic evaluation. Economic data collection measured by (1) Resource use 
schedules AD-SUS [41]; (2) EQ -5D-5L measure of health-related-quality of life [42]; and (3) the 
ICECAP-A measure of capabilities [43]. 
2.6.6 Process outcomes. We will conduct focus groups with participants and interviews with 
participating drug service staff and pharmacists to assess (from each perspective) the acceptability 
of the intervention and the trial procedures and also to determine how contextual factors and 
treatment process impact on feasibility criteria (including recruitment, take-up and compliance with 
assessments) the primary outcome (attendance).  
2.7 Participant timeline and study visits 
Participants will have a research assessment interview conducted by member of the research team 
at baseline and again at 12-14 weeks post-enrolment. (Figure 2. Consort). The baseline assessment 
will be conducted at the earliest opportunity after the participant has consented.  In addition to 
these interviews, towards the end of each participant’s intervention period (minimum 10 weeks 
post-enrolment) the researchers will approach all participants enrolled in the trial (whether or not 
they continue to receive the trial intervention), drug service keyworkers (whose patients have 
participated in the study) and pharmacists to ask them if they would be willing to participate in focus 
groups and interviews to provide information on their experience of taking part in the feasibility 
trial, using the tablet and receiving the telephone text message incentives or reminders. 
2.8 Sample size 
One of the aims of this feasibility trial is to estimate parameters needed for a sample size calculation 
for a larger confirmatory trial. Therefore, at this stage, no formal sample size/power calculation was 
undertaken. 
2.9 Randomisation 
The three sites will be randomly allocated to one of the following three arms :  
A. Supervised Medication + telephone delivered text messages providing positive 
reinforcement and modest financial incentives; 
B. Supervised Medication + telephone delivered text messages providing reminders only; or  
C. Supervised Medication with no telephone text messages (Treatment as Usual).  
Using simple randomisation in a 1:1:1 allocation ratio, sequences will be generated using a random 
number generator. Given small the number of sites to be randomised, there will be no blocking, 
stratification, or minimisation used in the randomisation procedures.  
2.10 Blinding 
Due to the nature of the intervention being studied, there will be no attempt at blinding either 
clinicians or participants. The researchers cannot be blinded due to the necessity to monitor the 
telephone system, with the analysing trial statistician unblinded in order to conduct the 
randomisation and monitor data. Only the senior trial statistician will be blind to treatment 
allocation throughout the study. 
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2.11 Data collection and management  
There will be five forms of data collection: 
Firstly, researchers will conduct face-to-face interviews with participants at baseline (after consent 
and immediately preceding enrolment onto the telephone system) and at 12 weeks post-enrolment. 
Interviews will be sought from all participants including those who discontinue receiving oral 
methadone treatment and/or discontinue receiving the telephone text message intervention as long 
as they do not withdraw consent for participation in feasibility trial/continued collection of their 
data. Participants will receive a £10 reimbursement for their time and travel for the baseline and 
follow-up interview.  
Secondly, the software system will collect information from participants via tablet computers in the 
pharmacies at each supervised methadone appointment over the 12-week period. This will record a 
patient nickname and telephone number, the date and time, and whether they attended and 
consumed their methadone or not. These data will be stored on a secure web site . At the end of the 
12-weeks intervention period, these data will be extracted from the software system by a research 
worker and entered into an SPSS database. This will be stored, along with other trial databases, with 
password protection on a secure KCL network drive. 
Thirdly, dispensing records kept by the allied pharmacies relating to trial participants will be 
provided to researchers after being pseudo-anonymised by the pharmacist (linked by nickname 
only). The pharmacist will have participants’ names and nickname stored in a password protected 
file. 
Fourth, interviews and focus groups involving patients (including those who have discontinued 
receiving the telephone system and/or those who have discontinued receiving oral methadone 
treatment), staff, and pharmacists will be recorded by digital handheld audio recorder (with 
encryption facilities) and uploaded and stored on a password protected secure KCL network drive. 
Patient participants will receive a £10 reimbursement for their time and travel for the focus group. 
Data from the baseline (0 weeks) and follow-up (12 weeks) interviews will be collected on paper 
case report forms (CRFs), which will be stored at KCL University. These data will be entered into SPSS 
databases by researchers at KCL University. Data from the telephone system will also be exported 
into an SPSS database. The SPSS databases will be developed by KCL researchers and statisticians. 
Data entry will be undertaken by KCL researchers. Range checks will be used. Data entry will be 
checked against paper case report forms in 10 per cent of participants to ensure accuracy of data 
entry, with higher order data queries undertaken by the analysing statistician. SPSS databases will be 
stored on a KCL secure drive, and will be subject to version control to allow for an audit trail of 
database changes. Only members of the KCL research team will have access. Data extracts will be 
provided to the trial statistician upon request. Copies of the Pharmacy Dispensing records will be 
stored at KCL University. 
2.12 Data monitoring 
A Data Monitoring and Ethnics Committee (DMEC) will be convened. The DMEC will be responsible 
for data monitoring throughout this feasibility trial. Monthly recruitment progress will be reported 
and compared to recruitment targets at each DMEC meeting. Adverse events will also be reported at 
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DMEC meetings, as detailed below. There are no interim analyses or audits of trial conduct planned. 
A Trial Steering Committee will be convened to provide independent expert advice on the ongoing 
conduct of the study. 
2.13 Data analysis 
A comprehensive statistical analysis plan will be developed and agreed with the trial’s oversight 
committees (DMEC and TSC).  All data will be analysed using R 3.5 [44] with the exception of the 
economic evaluation, focus groups and qualitative interviews. 
The feasibility outcomes will be summarised with appropriate summary statistics (generally 
frequencies and proportions). Differences between arms, where appropriate, will be assessed by 
examining differences in proportions. Estimates will be provided with 95% confidence intervals to 
provide an estimate of precision. 
The primary and secondary outcomes of a future confirmatory trial will also be summarised using 
appropriate statistics (e.g. mean and standard deviation/median and interquartile range for 
normally distributed/non-normally distributed continuous outcomes; counts and proportions for 
categorical outcomes). The outcome “number of days to missed dose” will likely be analysed using 
discrete-time survival analysis [45], although we may explore other methods. Differences between 
arms will be estimated as mean differences, difference in proportions, or by entering dummy 
variables into a regression model. Differences in survival outcome between arms will be expressed 
with hazard ratios. Associated confidence intervals will be estimated where appropriate. 
The primary purpose of these estimates is to inform sample size calculations of a future 
confirmatory trial. This analysis is not powered to detect differences between arms in the primary 
and secondary outcomes of a future confirmatory trial. Therefore, these estimates will be treated as 
exploratory and not used as the basis for inferential statements. These analyses will be done under 
the intention-to-treat principle. There will be no per-protocol or subgroup analyses. 
All efforts will be made to avoid missing baseline data (i.e. requiring completion of baseline data 
before randomisation), but if this occurs, missing values will be imputed according to current 
recommendations [46]. Missing scale item data will be handled as per questionnaire specific 
recommendations or, if no recommendations are available, pro-rating will be used (if less than 20% 
of items are missing the missing items will be replaced by the mean of the complete items). Given 
this is a feasibility study and the focus is not on between arm comparisons, multiple imputation for 
missing data will not be used. 
2.14 Economic data 
Data on health and social care service use will be collected using the Adult Service Use Schedule 
(AD-SUS), modified for use in substance misusing populations (41].  The feasibility of the AD-SUS will 
be explored based on completion rates, missing data (item missing, questionnaire missing), plausible 
values, and inconsistencies.  Service use data will be presented as means with appropriate measures 
of dispersion together with the proportion of participants reporting each resource use item.  We will 
use the EQ-5D-5L to measure health-related quality of life expressed as mean scores with 
appropriate measures of dispersion [47]. EQ-5D scores be calculated using 5L tariff and also the 3L 
tariff using the mapping function recommended by NICE [48].  We will also use the ICECAP-A to 
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measure changes in participants capability to undertake activities important to them [49]. We will 
explore the feasibility of the EQ-5D-5L and ICECAP-A measures with sensitivity to changes in 
comparable clinical outcomes (HADS, SF36 subscales) using appropriate measures of agreement.  
 
2.15 Process evaluation  
The qualitative process evaluation will generate evidence that supports refinement of the 
intervention and the proposed definitive trial. Specifically, we will assess (1) the acceptability of the 
intervention to participants (service-users) and clinicians; and (2) whether the intervention can be 
implemented in routine practice and delivered by staff who have the necessary capacity and 
competencies, and (3) the acceptability of trial procedures. Our qualitative design will involve both 
interviews and focus groups.  
Interviews will be undertaken with pharmacists and prescribers to assess acceptability and 
satisfaction with telephone delivered incentives and reminders, the impact of monitoring and 
reporting medication compliance to prescribers, resources required, the organisational impact (both 
drug service and pharmacy), and factors which help or hinder fidelity. Sampling of pharmacists and 
prescribers will be purposive, with participants identified based on their relationship to the 
intervention and propensity to provide an important or distinct perspective (pharmacists n=6; 
prescribers n=9).  
Focus-groups (n=6) will be used to obtain participant perspectives on using self-service internet-
login, receiving telephone delivered incentives and reminders, debit card payments and trial 
procedures (notably randomisation and assessment procedures) We have opted for focus groups (as 
opposed to 1-2-1 interviews) because they are efficient in reaching numbers of participants and 
ensuring attendance. They also facilitate participant interaction that supports reflection on the 
processes under study while (in this context) being low risk in terms of coverage of sensitive subject 
matter. 
All interviews/focus groups will be based on topic guides developed iteratively during the preceding 
study phases and applied flexibly to ensure coverage of key issues and responsiveness to emergent 
themes. Participants will be reimbursed £10 for attending a focus group.  
Interviews and focus groups will be audio recorded, transcribed verbatim and subject to a thematic 
analysis supported by NVIVO. The analysis will describe the different stakeholder experiences, and 
assess whether, how and to what extent, the professional, organisational and social contexts 
impacts on the delivery of the intervention and the acceptability and feasibility of trial procedures 
(particularly recruitment, follow-up and outcome assessment).  
Data will support refinement of the confirmatory trial intervention, trial design and the scope and 
focus of the process evaluation which will run concurrently with the planned future confirmatory 
trial. 
2.16 Adverse event monitoring 
We will monitor all non-serious adverse events, serious adverse events, and serious adverse 
reactions to trial interventions, serious deterioration, and active withdrawals from treatment. 
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Keyworkers and pharmacists will be asked to record events on a CRF and notify us if they are aware 
of any adverse events or active withdrawals from treatment. We will contact pharmacists and 
keyworkers once a week to monitor possible adverse reactions. These will be recorded in a specific 
SPSS database, stored on a secure KCL drive, and reported at each DMEC meeting. 
2.17 Progression criteria 
To proceed to a future confirmatory trial the following outcomes should be achieved. However, not 
achieving these criteria does not necessarily indicate unfeasibility of a future trial but underlines 
changes that need to be made to recruitment procedures, attendance record keeping and resources 
for follow-up. These include: 
• Recruitment of three drug services, two to three pharmacies and 60 participants (20 
from each drug service over 12 weeks); 
• 50% of target patients (those patients presenting to participating drug services for a new 
episode of opiate substitution treatment (OST) who have not been receiving a 
prescription for methadone or other opiate substitution medication for >4 weeks and 
who have not been transferred in from another service or prison) eligible and 
consented. 
• >95% consistency in recording of pharmacy attendance (comparing daily pharmacy 
dispensing records vs. self-service internet login). 
• Rates of follow-up at 12 weeks (>70%). 
• Completion rates of economic data collection (>70%),  
• Missing data (item missing/questionnaire missing) (<10% missing data per 
questionnaire) and inconsistencies. 
 
3. Discussion 
The TIES feasibility study seeks to assess the feasibility of conducting a future trial of delivering a 
behavioural intervention by telephone to improve medication adherence. There is little work in this 
area. Findings from this study will be assessed against progression criteria to inform a future 
confirmatory trial. 
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